International Journal of Hematology

, Volume 94, Issue 1, pp 71–80 | Cite as

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial

  • Yukari Shirasugi
  • Kiyoshi Ando
  • Koji Miyazaki
  • Yoshiaki Tomiyama
  • Shinichiro Okamoto
  • Mineo Kurokawa
  • Keita Kirito
  • Yuji Yonemura
  • Shinichiro Mori
  • Kensuke Usuki
  • Koji Iwato
  • Satoshi Hashino
  • Helen Wei
  • Richard Lizambri
Original Article


The efficacy and safety of romiplostim, a thrombopoietin-mimetic peptibody, were evaluated in a double-blind, placebo-controlled, randomized trial of Japanese patients with chronic immune thrombocytopenia (ITP). Thirty-four ITP patients received romiplostim (n = 22) or placebo (n = 12) for 12 weeks, with a starting romiplostim dose of 3 μg/kg weekly. The primary end point was the number of weeks with platelet response, defined as a platelet count ≥50 × 109/L (not including the 4 weeks after rescue medication administration). Patients received a median of 4 (range 1–19) prior ITP therapies including splenectomy in 44%. On study, 68% also received concomitant ITP therapy. Weekly responses occurred for a median of 11 weeks with romiplostim as compared to 0 weeks with placebo (p < 0.0001). Most romiplostim-treated patients (95%) achieved platelet responses; two showed extended responses after the treatment period. The use of rescue medication was required in 9% of romiplostim-treated patients as compared with 17% of placebo-treated patients. Both treatment groups had similar incidences of adverse events (91% romiplostim, 92% placebo). Adverse events that occurred more frequently (>10%) in romiplostim-treated patients included nasopharyngitis, headache, peripheral edema, back pain, and extremity pain. In conclusion, romiplostim significantly increased and maintained platelet counts and was well tolerated in Japanese patients with ITP.


Idiopathic thrombocytopenic purpura TPO-receptor agonist Japan Efficacy Safety 


  1. 1.
    Kurata Y. Recent advances in the treatment of idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 2007;48:355–62.PubMedGoogle Scholar
  2. 2.
    Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887–95.PubMedCrossRefGoogle Scholar
  3. 3.
    Ijichi T, Muranishi M, Shimura K, et al. Idiopathic thrombocytopenic purpura and mononeuropathy multiplex. Acta Haematol. 2003;110:33–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146:585–96.PubMedCrossRefGoogle Scholar
  5. 5.
    Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol Suppl. 2009;(71):8–12.CrossRefGoogle Scholar
  6. 6.
    Pruemer J. Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. Am J Health Syst Pharm. 2009;66:S4–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang F, Chu X, Wang L, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76:427–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Deane S, Teuber SS, Gershwin ME. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev. 2010;9:A342–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am. 2009;23:1213–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.PubMedCrossRefGoogle Scholar
  12. 12.
    Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98:436–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Arnold DM, Stasi R. Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H. pylori infection? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program. 2008;31–2.Google Scholar
  15. 15.
    Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol. 2006;84:309–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Suzuki T, Matsushima M, Masui A, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura—a randomized controlled trial. Am J Gastroenterol. 2005;100:1265–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Tsumoto C, Tominaga K, Okazaki H, et al. Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol. 2009;88:789–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83:83–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145:235–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Kurata Y, Fujimura K, Kuwana M, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79:504–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Godeau B, Michel M. Treatment of chronic immune thrombocytopenic purpura in adults. Ann Hematol. 2010;89:55–60.Google Scholar
  24. 24.
    McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126:307–14.PubMedGoogle Scholar
  25. 25.
    Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;100:728–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics. 2010;4:139–45.PubMedGoogle Scholar
  27. 27.
    Nplate (romiplostim), European Public Assessment Report. European Medicines Agency. 2009. Available at Accessed 16 June 2011.
  28. 28.
    Romiplate prescribing information. 2011. Accessed 16 June 2011.
  29. 29.
    Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94:1–26.PubMedGoogle Scholar
  30. 30.
    Matthews HW. Racial, ethnic and gender differences in response to medicines. Drug Metabol Drug Interact. 1995;12:77–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Kumagai Y, Fujita T, Ozaki M, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol. 2007;47:1489–97.PubMedCrossRefGoogle Scholar
  32. 32.
    Shirasugi Y, Ando K, Hashino S, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90:157–65.PubMedCrossRefGoogle Scholar
  33. 33.
    Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.PubMedCrossRefGoogle Scholar
  35. 35.
    Jawa V, Hokom M, Hu Z, et al. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann Hematol 2010.Google Scholar
  36. 36.
    Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:39–41.CrossRefGoogle Scholar
  37. 37.
    Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113:2161–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393–402.PubMedCrossRefGoogle Scholar
  39. 39.
    Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114:3748–56.PubMedCrossRefGoogle Scholar
  40. 40.
    Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889–99.PubMedCrossRefGoogle Scholar
  41. 41.
    Saleh MN, Bussel JB, Meyer O, et al. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag [abstr]. Blood. 2009;114:1326.Google Scholar
  42. 42.
    Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51:842–56.PubMedCrossRefGoogle Scholar
  43. 43.
    Promacta (eltrombopag) tablets. US prescribing information. GlaxoSmithKline: Research Triangle Park; 2010.Google Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Yukari Shirasugi
    • 1
  • Kiyoshi Ando
    • 1
  • Koji Miyazaki
    • 2
  • Yoshiaki Tomiyama
    • 3
  • Shinichiro Okamoto
    • 4
  • Mineo Kurokawa
    • 5
  • Keita Kirito
    • 6
  • Yuji Yonemura
    • 7
  • Shinichiro Mori
    • 8
  • Kensuke Usuki
    • 9
  • Koji Iwato
    • 10
  • Satoshi Hashino
    • 11
  • Helen Wei
    • 12
  • Richard Lizambri
    • 13
  1. 1.Department of Hematology and OncologyTokai University HospitalIseharaJapan
  2. 2.Department of HematologyKitasato University HospitalKanagawaJapan
  3. 3.Department of Blood TransfusionOsaka University HospitalOsakaJapan
  4. 4.Division of HematologyKeio University HospitalTokyoJapan
  5. 5.Department of Hematology and OncologyThe University of Tokyo HospitalTokyoJapan
  6. 6.Department of Hematology and OncologyUniversity of Yamanashi HospitalYamanashiJapan
  7. 7.Department of Transfusion Medicine and Cell TherapyKumamoto University HospitalKumamotoJapan
  8. 8.Department of Hematology and OncologyKansai Medical University Hirakata HospitalOsakaJapan
  9. 9.Division of HematologyNTT Kanto Medical CenterTokyoJapan
  10. 10.Department of Blood TransfusionHiroshima Red Cross Hospital and Atomic-bomb Survivors HospitalHiroshimaJapan
  11. 11.Department of Gastroenterology and HematologyHokkaido University HospitalHokkaidoJapan
  12. 12.Biostatistics, Amgen Inc.Thousand OaksUSA
  13. 13.Clinical Development, Amgen Inc.Thousand OaksUSA

Personalised recommendations